William Blair acted as the exclusive financial advisor to PronoKal Group, a portfolio company of Abac Capital, in connection with its pending sale to Nestlé Health Science (NHSc). The transaction has been signed and is expected to close in Q1 2022.
About the Companies
PronoKal Group is a leading player in the European medical weight loss treatment market, providing a science-backed multi-disciplinary treatment method which combines medical prescription, high quality dietary products, nutritional coaching, physical training and applied genomics. PronoKal Group was founded in 2004 and is based in Barcelona, Spain.
Abac Capital is a Barcelona based private equity fund with institutional investors from Europe, the United States and the Asia-Pacific region that invests in Spain-based SMEs. The Abac team has a track record across a wide variety of sectors, countries, development stages and equity and debt-like instruments.
Nestlé Health Science, a wholly-owned subsidiary of Nestlé (SIX:NESN), is a globally recognized leader in the field of nutritional science. NHSc is committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. The company offers an extensive consumer health portfolio of industry-leading medical nutrition, consumer and vitamins, minerals, and supplements brands that are science-based solutions covering all facets of health from prevention, to maintenance, to treatment.
Nestlé is the world largest food and beverage company, which manufactures and markets a wide range of products. The Nestlé brand portfolio covers foods, beverages, and nutritional health solutions. The company stands out for its market leading nutrition science offering and strong commitment towards enhancing consumer health.
Learn more about our consumer and retail and healthcare services investment banking expertise.